Erschienen in:
01.10.2008 | Preclinical Study
Expression of the forkhead transcription factor FOXP1 is associated with that of estrogen receptorβ in primary invasive breast carcinomas
verfasst von:
Gaynor J. Bates, Stephen B. Fox, Cheng Han, Rosalind Launchbury, Russell D. Leek, Adrian L. Harris, Alison H. Banham
Erschienen in:
Breast Cancer Research and Treatment
|
Ausgabe 3/2008
Einloggen, um Zugang zu erhalten
Abstract
We previously identified a correlation between estrogen receptor alpha (ERα) and the candidate tumour suppressor gene Forkhead Box P1 (FOXP1), whose nuclear protein expression in breast tumours was associated with improved patient survival. However, the expression pattern of FOXP1 in normal breast tissue is more reminiscent of the second receptor, ERβ, which has an emerging role as a tumour suppressor in breast cancer and critically may underlie the ability of some ERα-negative tumours to respond to tamoxifen. In a series of 283 breast cancers, in which ERα-positive tumours were treated with tamoxifen, the nuclear expression of ERβ correlated significantly with ERα (p = 0.004), low-tumour grade (p = 0.008) and nuclear FOXP1 (p = 0.01). High-grade tumours exhibited significantly more cytoplasmic ERβ than the low-grade tumours (p = 0.006). Regression analysis demonstrated that FOXP1 expression was most closely related to nuclear ERβ (p = 0.021). Neither, nuclear or cytoplasmic ERβ expression demonstrated prognostic significance. FOXP1 is not estrogen regulated and silencing FOXP1 expression, using siRNA, did not affect ERα, ERβ or progesterone receptor expression, suggesting ER and FOXP1 co-expression may reflect a common regulatory mechanism.